Join
Live feed
·
PRReleasevia Quantisnow
Lexeo Therapeutics Inc. logo

Lexeo Therapeutics Announces Investor Webcast to Report Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy on Monday, July 15, 2024

ByQuantisnow·Wall Street's wire, on your screen.
LXEO· Lexeo Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track LXEO (Lexeo Therapeutics Inc.) and more on Quantisnow.